Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

about

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.

Item

http://www.wikidata.org/entity/Q48296982

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@en

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@nl

type

Item

label

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@en

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@nl

prefLabel

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@en

Predictive biomarkers and prac ...... mib-associated cardiotoxicity.

@nl

P1476

Predictive biomarkers and prac ...... omib-associated cardiotoxicity

@en

P2093

Aeri Alexander

http://www.w3.org/2001/XMLSchema#string

Andrea Ballagi

http://www.w3.org/2001/XMLSchema#string

David J Chung

http://www.w3.org/2001/XMLSchema#string

Eric Smith

http://www.w3.org/2001/XMLSchema#string

Guenther Koehne

http://www.w3.org/2001/XMLSchema#string

Gunjan L Shah

http://www.w3.org/2001/XMLSchema#string

Hani Hassoun

http://www.w3.org/2001/XMLSchema#string

Ida Grundberg

http://www.w3.org/2001/XMLSchema#string

Ioanna Tsakos

http://www.w3.org/2001/XMLSchema#string

Minal Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib

Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Management of Carfilzomib-Associated Cardiac Adverse Events.

'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.

P304

1981-1985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1403020

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ola Landgren

Alexander M Lesokhin

Heather Landau

P577

2018-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29308691

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

6162998

http://www.w3.org/2001/XMLSchema#string